Neffy (Credit: neffy website)
November 11, 2024 07:20 AM ESTUpdated 02:08 PM
Deals
Pharma

Dan­ish com­pa­ny pays $145M up­front to li­cense nasal spray al­ter­na­tive to EpiPen

Ayisha Sharma

News Reporter

A Dan­ish com­pa­ny is spend­ing $145 mil­lion up­front for cer­tain rights to the first-ever nee­dle-free adren­a­line nasal spray for se­vere al­ler­gic re­ac­tions, un­lock­ing sales po­ten­tial …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Take­da to pay $200M for rights to ane­mia drug from Keros

Rev­o­lu­tion sells $600M in shares on back of RAS in­hibitor port­fo­lio up­dates

Janux soars on ear­ly prostate can­cer da­ta that could chal­lenge No­var­tis' Plu­vic­to

Ipsen se­cures rights to pre­clin­i­cal T cell en­gager in $610M pact with French biotech

Roche teams up with Chica­go au­toim­mune biotech COUR Phar­ma­ceu­ti­cals

Gilead makes an­oth­er ADC move, ink­ing up to $415M pact with Tubu­lis

A service from the Financial Times